One of the largest hurdles that healthcare practitioners treating epilepsy need to overcome is often with their own patients. It turns out that an estimated 30 to 50 percent of epilepsy patients don’t adhere to the drug regimens prescribed to them. The reasons for noncompliance, however, are rarely due to patient’s being willfully defiant of their doctor’s orders, but often much more mundane. Forgetting to take pills regularly is common for all of us, and for some patients, specifically the elderly and children, taking larger pills is often quite difficult for medical reasons, as well as simply having aversions to swallowing large dose pills.
It was with these patients in mind that Aprecia Pharmaceuticals, which specializes in developing new ways to help patients maintain compliance with their prescribed medication regimen, developed a process to make large dose medication easier to swallow using 3D printing technology. Their new manufacturing process was designed to create large dose dissolvable versions of popular medications that would not need to be swallowed. The first medication made using this process was for a commonly prescribed anticonvulsant called levetiracetam that Aprecia says will dissolve in the mouth with a small sip of liquid.
Here is a video demonstration showing exactly how quickly the pill will dissolve:
Levetiracetam is typically sold using the brand name Keppra and has already been made available in several strengths as a tablet, a liquid, and an extended-release formulation. It is typically used to help treat a wide variety of seizures in both epileptic adults and children, including myoclonic seizures, partial-onset seizures and primary generalized tonic-clonic seizures. The largest dose available, 1,000 mg, will be a rather large pill measuring about the diameter of a nickel and a height of four nickels, however because of the pill’s porous nature it won’t actually need to be swallowed but the patient can simply allow it to dissolve.
Aprecia says that the 3D printing process that they developed, called ZipDose, will make it easier for patients who are required to take large dose medications or a large number of pills daily. The proprietary manufacturing technique developed by MIT is a familiar process to the 3D printing industry. The printer is mechanically quite similar to a sand 3D printer or the Selective Laser Sintering process sans the laser. The printer will lay down a very fine layer of the drug in powder form, a printing head runs over it, dropping a small amount of a binding agent into the power and the process repeats until the pill is fully formed.
In an interview with Neurology Today, the chief executive officer of Aprecia, Don Wetherhold, explained that the 3D printed pill was porous, which would allow it to dissolve in the patient’s mouth very quickly with just a sip of liquid. The pill can vary in dosage depending on the needs of the patient, and the process even allows extremely large doses, up to 1,000 mg, to be made into a relatively compact pill.
“It has a unique capacity to dissolve at higher-dose loads. There clearly are some patients who would benefit — children, the elderly, people who have some other condition that may make it hard to swallow, such as cerebral palsy, stroke, or Alzheimer’s disease,” Wetherhold said.
The 3D printed levetiracetam pill was officially approved for use by the US Food and Drug Administration (FDA) this past August and is expected to be available sometime in 2016. Each pill will be individually packaged, and while Aprecia did not have any pricing information it is expected to be in-line with other formulations of the drug. This new version of levetiracetam will be marketed as Spritam. Aprecia is calling it the first drug manufactured using a 3D printing process, an assertion that is only partially true. Spritam will simply be the first 3D printed drug that has been approved for use, but the concept has been experimented with in the medical 3D printing market for several years now.
Let’s hear your thoughts on the use of 3D Printing within the drug industry. Discuss in the Aprecia forum thread on 3DPB.com.
You May Also Like
3D Printing News Briefs, October 13, 2021: Metal 3D Printing, Prostheses, & More
In today’s 3D Printing News Briefs, ExOne and SSI are working together to drive volume production with metal binder jet 3D printing, and RadTech has announced a new photopolymer AM...
3D Printing Shrinks Lab-on-a-Chip Devices Even Smaller
Microfluidic devices are tiny microchips that have almost completely microscopic channels, pumps, and valves etched into them for the purposes of sorting and analyzing cells, disease biomarkers, and other miniature...
3D Printing News Briefs, October 6, 2021: Business, Guns, & Bridges
We’re starting with a little business in today’s 3D Printing News Briefs, as EPLUS 3D and Shining 3D have issued a joint declaration. Optomec received an order from an OEM...
Metal 3D Printing Sustainability to Be Studied by Yale via $100K AMGTA Grant
“Industrial ecology” might sound like an oxymoron, but it’s also an extremely important framework for estimating the long-term sustainability of the business models fundamental to any economy’s critical infrastructure. Yale’s...
View our broad assortment of in house and third party products.